Provided by Tiger Fintech (Singapore) Pte. Ltd.

NanoVibronix Inc

3.43
+1.2255.49%
Pre-market: 3.23-0.2000-5.83%05:07 EDT
Volume:42.18M
Turnover:147.72M
Market Cap:2.72M
PE:-0.26
High:4.15
Open:3.87
Low:2.78
Close:2.21
Loading ...

Top Premarket Gainers

MT Newswires Live
·
Yesterday

Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal

Business Wire
·
14 Mar

NanoVibronix Inc trading halted, news pending

TIPRANKS
·
14 Mar

NanoVibronix Completes ENvue Medical Acquisition

MT Newswires Live
·
14 Feb

NanoVibronix completes acquisition of ENvue Medical

TIPRANKS
·
14 Feb

Nanovibronix, Inc. Announces Acquisition of Envue Medical Holdings, Corp.

THOMSON REUTERS
·
14 Feb

NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp.

Business Wire
·
14 Feb

BRIEF-Nanovibronix Advances Development Of Painshield And Uroshield With Completion Of Nextgen Prototypes

Reuters
·
07 Jan

Nanovibronix Advances Development of Painshield and Uroshield With Completion of Nextgen Prototypes

THOMSON REUTERS
·
07 Jan

BRIEF-Nanovibronix Completes Pilot Phase Of Clinical Study Of Uroshield At The University Of Michigan

Reuters
·
06 Jan

Nanovibronix Announces Completion of Pilot Phase of Clinical Study of Uroshield® at the University of Michigan

THOMSON REUTERS
·
06 Jan

NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan

Business Wire
·
06 Jan

NanoVibronix gets $12M purchase deal for PainShield, extends distribution pact

TIPRANKS
·
11 Dec 2024

Nanovibronix Secures $12 Million Minimum Purchase Commitment for Painshield With Extension of Distribution Agreement

THOMSON REUTERS
·
11 Dec 2024

NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement

Business Wire
·
11 Dec 2024

NanoVibronix Third Quarter 2024 Earnings: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023)

Simply Wall St.
·
17 Nov 2024